Answers are grounded in this paper and cite their sources.
Pulmonary arterial hypertension (PAH) is a rare disease with poor prognosis. The same treatment is recommended in patients with PAH associated with connective tissue disease (CTD) and idiopathic PAH (IPAH). However, the effectiveness of PAH‐specific treatment in these both groups is inconsistent. The study incorporated data from the prospective, multicentre polish registry (BNP‐PL) by comparison of baseline versus 1‐year follow‐up clinical, laboratory, echocardiographic and hemodynamic parameters in PAH‐CTD versus IPAH group. The all‐cause 1‐year mortality was also analysed. 624 patients were included in the study: 176 (28%) PAH‐CTD and 448 (72%) IPAH. 48 (8% of the total 624) patients died during 1‐year follow up: 32 (7%) with IPAH and 16 (9%) with PAH‐CTD ( p = 0.4). The effectiveness of treatment was examined in 421 patients: 115 (27%) PAH‐CTD and 306 (73%) IPAH. The improvement of treatment was effective in both groups in terms of WHO FC ( p < 0.001 in both groups), 4‐strata risk model ( p < 0.001 in both groups), 6 min walking test (6MWT, p < 0.001 in IPAH, p = 0.001 in PAH‐CTD), Δ6MWT ( p = 0.19 between PAH‐CTD and IPAH), tricuspid annular plane systolic excursion ( p < 0.001 in both groups), NT‐ proBNP ( p < 0.001 in IPAH and p < 0.01 in PAH‐CTD), mean pulmonary arterial pressure ( p = 0.043 in IPAH and p = 0.01 in PAH‐CTD), pulmonary vascular resistance ( p < 0.001 in both groups) and cardiac output ( p < 0.001 in IPAH and p = 0.034 in PAH‐CTD). PAH specific treatment in PAH‐CTD patients is as effective as in IPAH patients regarding improvement in WHO FC, 4‐strata risk model, 6MWT, Δ6MWT, TAPSE, NT‐proBNP, mPAP, PVR and CO at 1‐year follow‐up. 1‐year all‐cause mortality was not significantly different between PAH‐CTD and IPAH patients.
No takes yet. Share an insight, caveat, or question.
Smukowska‐Gorynia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: